Cerca un farmaco orfano
Altra/e opzione/i di ricerca
Autorizzazione all’immissione in commercio senza designazione orfana - Europa
- denominazione commerciale: KIOVIG
- Codice ATC : J06BA02
- Numero EU: EU/1/05/329/...
- AIC data : 19/01/2006
- Titolare dell'AIC: BAXTER AG
- Relazione di Valutazione Pubblica Europea (EPAR)
Therapeutic indication
*Replacement therapy in adults, and children and adolescents (0-18 years) in:
- Primary immunodeficiency syndromes with impaired antibody production,
- Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed,
- Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation,
- Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT).
*Immunomodulation in adults, and children and adolescents (0-18 years) in:
- Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count,
- Guillain Barré syndrome,
- Kawasaki disease,
- Multifocal Motor Neuropathy (MMN).
Elenco delle malattie
- Immunodeficienza che interessa prevalentemente la produzione di anticorpi
- Malattia di Kawasaki
- Neuropatia motoria multifocale
- Porpora trombocitopenica immune
- Sindrome di Evans
- Sindrome di Guillain-Barré